TURN-COVID Biobank: The Dutch cohort study tor the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 400
- 试验地点
- 4
- 主要终点
- What are the SARS-CoV-2 viral load kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2 and the occurence of SARS-CoV-2 infection when used as a prophylactic?
研究概览
简要总结
- A. What are the SARS-CoV-2 viral load kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2 and the occurence of SARS-CoV-2 infection when used as a prophylactic?
- B. Do viral variants, spike mutations and immune escape occur during treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2?
- C. What are the viral antibody and inflammatory response kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2?
- D. To create a biobank to address future questions regarding the current use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2 compared to novel Covid-19 treatments which are in development.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •All patients that are treated with neutralizing SARS-CoV-2 antibodies and other antivirals against or as prevention of SARS-CoV-2 as standard of care.
- •Patients have to be aged ≥ 18 y.
排除标准
- •No informed consent is provided by the patient.
- •Patients not suitable to fulfil study procedures
结局指标
主要结局
What are the SARS-CoV-2 viral load kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2 and the occurence of SARS-CoV-2 infection when used as a prophylactic?
What are the SARS-CoV-2 viral load kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2 and the occurence of SARS-CoV-2 infection when used as a prophylactic?
Do viral variants, spike mutations and immune escape occur during treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2?
Do viral variants, spike mutations and immune escape occur during treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2?
What are the viral antibody and inflammatory response kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2?
What are the viral antibody and inflammatory response kinetics during and after treatment with neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2?
To create a biobank to address future questions regarding the current use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2 compared to novel COVID-19 treatments which are in development.
To create a biobank to address future questions regarding the current use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2 compared to novel COVID-19 treatments which are in development.
次要结局
未报告次要终点
研究者
Joost W. Wiersinga
Scientific
Stichting Amsterdam UMC